Skip to content

Establishment of the big data cloud platform of the minimally invasive meridian diagnosis and treatment center and the application of date of the minimally invasive needle-knife endoscope of RA patients in early diagnosis research

Establishment of the big data cloud platform of the minimally invasive meridian diagnosis and treatment center and the application of date of the minimally invasive needle-knife endoscope of RA patients in early diagnosis research

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064165
Enrollment
Unknown
Registered
2022-09-28
Start date
2022-09-29
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

RA group:Needle knife mirror
OA group: Needle knife mirror

Sponsors

General Hospital of Southern Theatre Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the classification criteria of rheumatoid arthritis jointly formulated by ACR/EULAR in 2010; 2. Patients who meet the diagnostic criteria for knee osteoarthritis formulated by the Orthopedic Branch of the Chinese Medical Association in 2010; 3. Aged 18-60 years.

Exclusion criteria

Exclusion criteria: 1. Severe infection history in the last month; 2. Patients with severe diseases of respiratory system, cardiovascular system, digestive system, urinary system, blood system and other important organs, as well as severe extraarticular manifestations such as constrictive pericarditis, vasculitis, secondary Sjogren's syndrome and other patients requiring glucocorticoids; 3. Overlapping syndromes with other rheumatic diseases; 4. Patients with HIV infection and malignant tumor; 5. Pregnant and lactating women, women with family planning and mental patients; 6. Patients who are allergic to lidocaine or cannot be treated by intramuscular minimally invasive therapy; 7. Does not meet the above diagnostic criteria; Patients without informed consent; Patients who may not be able to complete the whole process of this study; The investigator considers it inappropriate to conduct this clinical trial.

Design outcomes

Primary

MeasureTime frame
Erythrocyte sedimentation rate;C-reactive protein;Inflammatory cytokines;rheumatoid factor;Immunohistochemistry;VAS;Synovial scoring under microscope;

Countries

China

Contacts

Public ContactYingwan Liu

Department of Chinese Medicine and Rheumatology, General Hospital of Southern Theatre Command, Peoples R China

515789010@qq.com+86 13763385915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026